Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hepatic Encephalopathy - Overview
Hepatic Encephalopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hepatic Encephalopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatic Encephalopathy - Companies Involved in Therapeutics Development
AlfaSigma SpA
Ferring Intertiol Center SA
Gilead Sciences Inc
Grifols SA
Kaleido Biosciences Inc
MallInckrodt Plc
Spherium Biomed SL
Synlogic Inc
Umecrine Cognition AB
Hepatic Encephalopathy - Drug Profiles
albumin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GR-3027 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KB-174 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KLS-13019 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ornithine phenylacetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBX-2660 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rifaximin SSD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selonsertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYNB-1020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THDP-17 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hepatic Encephalopathy - Dormant Projects
Hepatic Encephalopathy - Product Development Milestones
Featured News & Press Releases
Oct 20, 2017: Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting
Aug 23, 2017: Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting 2017
Jun 01, 2017: Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis
May 26, 2017: Ocera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease
Mar 08, 2017: Ocera to Announce Additiol Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic Encephalopathy
Jan 30, 2017: Ocera Announces Top-line Results for Phase 2b Study in Hepatic Encephalopathy
Jan 05, 2017: Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis
Dec 07, 2016: Ocera Completes Enrollment of STOP-HE, a Phase 2b Study of OCR-002 in Hospitalized Patients with Hepatic Encephalopathy
Nov 02, 2016: Ocera Therapeutics: Update on OCR-002
Sep 19, 2016: Ocera Initiates Phase 1 Clinical Study of Orally Available OCR-002 in Patients with Cirrhosis for the Prevention of Hepatic Encephalopathy
Apr 15, 2016: Ocera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia Scavenger OCR-002 at The Intertiol Liver Congress 2016 of the European Association for the Study of the Liver (EASL)
Apr 11, 2016: Ocera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia Scavenger OCR-002 in the Jourl of Hepatology
Jan 08, 2016: Ocera Announces Complete Plasma Data From Pilot Phase 1 Study for Orally-Available OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy
Nov 16, 2015: Ocera Announces Positive Phase 1 Results for Oral OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy
Sep 16, 2015: Ocera Initiates Phase 1 Clinical Trial of Oral Drug Candidate OCR-002 for Prevention of Hepatic Encephalopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Hepatic Encephalopathy, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Targets, H1 2019
Number of Products by Stage and Targets, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019


List of Tables


Number of Products under Development for Hepatic Encephalopathy, H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Hepatic Encephalopathy - Pipeline by AlfaSigma SpA, H1 2019
Hepatic Encephalopathy - Pipeline by Ferring International Center SA, H1 2019
Hepatic Encephalopathy - Pipeline by Gilead Sciences Inc, H1 2019
Hepatic Encephalopathy - Pipeline by Grifols SA, H1 2019
Hepatic Encephalopathy - Pipeline by Kaleido Biosciences Inc, H1 2019
Hepatic Encephalopathy - Pipeline by MallInckrodt Plc, H1 2019
Hepatic Encephalopathy - Pipeline by Spherium Biomed SL, H1 2019
Hepatic Encephalopathy - Pipeline by Synlogic Inc, H1 2019
Hepatic Encephalopathy - Pipeline by Umecrine Cognition AB, H1 2019
Hepatic Encephalopathy - Dormant Projects, H1 2019